Keith J. Kendall
Net Worth
Last updated:
What is Keith J. Kendall net worth?
The estimated net worth of Mr. Keith J. Kendall is at least $9,689,180 as of 30 Jun 2020. He owns shares worth $2,479,180 as insider and has received compensation worth at least $7,210,000 in Aquestive Therapeutics, Inc..
What is the salary of Keith J. Kendall?
Mr. Keith J. Kendall salary is $1,030,000 per year as Chief Executive Officer, Pres & Director in Aquestive Therapeutics, Inc..
How old is Keith J. Kendall?
Mr. Keith J. Kendall is 67 years old, born in 1958.
What stocks does Keith J. Kendall currently own?
As insider, Mr. Keith J. Kendall owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer, Pres & Director | 638,964 | $3.88 | $2,479,180 |
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Keith J. Kendall insider trading
Aquestive Therapeutics, Inc.
Mr. Keith J. Kendall has made only one insider trade between 2018-2020, according to the Form 4 filled with the SEC.
As of 30 Jun 2020 he still owns at least 638,964 units of AQST stock.
Aquestive Therapeutics key executives
Aquestive Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Mr. Daniel Barber (49) Senior Vice President & Chief Operating Officer
- Mr. Keith J. Kendall (67) Chief Executive Officer, Pres & Director